Data di Pubblicazione:
2016
Citazione:
An update on the strategies used for the treatment of chronic hepatitis B in children / Clemente, Maria Grazia; Vajro, P.. - In: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 1747-4124. - (2016). [10.1586/17474124.2016.1139450]
Abstract:
Chronic hepatitis B (CHB) in children shows a variety of clinical presentations, which
influence its natural course and treatment options. This report provides an overview of
the ongoing strategies in pediatric CHB management. Interferon-represents the first
choice of treatment in children showing HBV replication and hepatic inflammation
(immune active CHB), while the recommendation is to monitor inactive/immunetolerant
children (normal transaminases and low/absent viral replication). When
circumstances preclude the use of Interferon-and in cases of
compensated/decompensated cirrhosis, entecavir for children above 2 years of age or
tenofovir for children above 12 years of age are the nucleos(t)ide analogues
recommended by the most recent guidelines.
influence its natural course and treatment options. This report provides an overview of
the ongoing strategies in pediatric CHB management. Interferon-represents the first
choice of treatment in children showing HBV replication and hepatic inflammation
(immune active CHB), while the recommendation is to monitor inactive/immunetolerant
children (normal transaminases and low/absent viral replication). When
circumstances preclude the use of Interferon-and in cases of
compensated/decompensated cirrhosis, entecavir for children above 2 years of age or
tenofovir for children above 12 years of age are the nucleos(t)ide analogues
recommended by the most recent guidelines.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
HBV infection, antiviral therapy, interferon, entecavir, children
Elenco autori:
Clemente, Maria Grazia; Vajro, P.
Link alla scheda completa:
Pubblicato in: